Factors Related to Liver Stiffness in Patients with Hepatitis C During Direct-acting Antiviral Agent Treatment by Ryosaku Shirahashi et al.
Factors related to liver stiffness??（2）（2019） 55
????????????
In recent years, methods that measure liver stiff-
ness non-invasively with ultrasound, such as acoustic 
radiation force impulse imaging（ARFI）1）, transient 
elastography（TE）2）, and strain elastography（SE）3）, 
have been reported to be useful in evaluating hepatic 
fibrosis. Shear wave elastography（SWE）is a new 
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technology that gauges liver stiffness by measuring 
the propagation velocity of shear waves（Vs）generat-
ed in liver tissue. Vs measurements with SWE are 
reported to be useful in diagnosing the fibrosis in hep-
atitis C patients 4）.
It has been previously reported that, in hepatitis C 
patients, liver stiffness measured by SWE was higher 
in the naïve group than in the sustained virological 
response（SVR）group, presumably due to hepatitis 
activity 5）. Improvement of liver stiffness compared 
with the pre-treatment level was reported in hepatitis 
C patients who achieved SVR by treatment with 
direct-acting antiviral agents（DAAs）6）, and this 
improvement of liver stiffness was shown to be more 
prominent in hepatitis C patients with advanced fibro-
sis 7,8）.
The purpose of this study was to observe the 
changes over time in liver stiffness measured by SWE 
in hepatitis C patients during DAA treatment and 
evaluate the factors affecting liver stiffness.
???????
Patients
The subjects were 206 consecutive patients diag-
nosed with hepatitis C patients in the Dokkyo Medical 
University Saitama Medical Center who were treated 
with DAAs between July 2015 and February 2016. 
Patients with decompensated liver cirrhosis, hepatocel-
lular carcinoma, autoimmune disease, collagen disease, 
or chronic heart disease were excluded. Patients with 
a history of drinking ≥ 20 g alcohol per day and those 
diagnosed with obvious fatty liver on abdominal ultra-
sound were also excluded.
This prospective study was approved by the Ethics 
Committee of the Dokkyo Medical University Saitama 
Medical Center, and written, informed consent was 
obtained from all participants. This study conformed 
to the ethical guidelines of the 2008 Declaration of 
Helsinki.
Measurement of the Velocity of the Shear Wave
Measurement of Vs by SWE was performed using a 
LOGIQ E9（GE Healthcare, Milwaukee, WI, USA）. 
The right lobe of the liver was visualized through an 
intercostal space while the patient was lying in a 
supine position with the right arm in maximum 
abduction. Measurements were taken while subjects 
held their breath during spontaneous breathing. The 
visual depth of the system was fixed at 8 cm, and the 
region of interest（ROI）was 1-2 cm below the surface 
of the liver. The system was adjusted so that sample 
volume depth was 4 cm or less. The apparatus auto-
matically calculated the Vs, and the results are 
expressed in m/s. The result was considered reliable 
only when 10 successful shots and a measurement 
success rate＞80％ were obtained.
The duration of DAAs treatment of all patients was 
12 weeks. SWE was performed before starting treat-
ment（baseline）, at the end of treatment（EOT）, and 
12 weeks after EOT（follow-up 12）. The change in Vs
（ΔVs）was calculated for the difference between base-
line and follow-up 12.
Clinical parameters
Clinical parameters, which were obtained on the 
same day that SWE was performed, were compared. 
Clinical parameters other than Vs were the follow-
ing：aspartate aminotransferase（AST）, alanine ami-
notransferase（ALT）, total bilirubin（T-Bil）, albumin
（Alb）, leukocytes（WBC）, hemoglobin（Hb）, platelets
（Plt）, prothrombin time％（PT％）, a -fetoprotein
（AFP）, and Mac-2 binding protein glycosylation-iso-
mer（M2BPGi）. These parameters were measured on 
the same days as SWE. The FIB-4 index was estimat-
ed using the values of serum AST, ALT, Plt, and age. 
ΔALT, ΔAFP, and ΔM2BPGi were calculated with 
differences between baseline and follow-up 12, similar 
to ΔVs.
Each parameter at baseline, ΔALT, ΔAFP, and Δ
M2BPGi were used as explanatory variables in multi-
ple regression analysis.
Statistical analysis
Continuous data for liver stiffness and other clinical 
parameters are expressed as means±standard devia-
tion（SD）. A paired Wilcoxon test was used to test for 
differences in each parameter before and after the 
start of treatment. Friedman’s test was used to test 
multiple comparisons of each parameter. Multiple 
regression analysis was used to examine the factors 
that contributed to ΔVs. Values of P＜0.05 were 
regarded as significant.
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A total of 206 consecutive hepatitis C patients were 
recruited for the study. Twenty-nine of these 
patients, including six patients with a history of HCC, 
20 patients diagnosed with fatty liver by ultrasound, 
and 9 patients with a history of drinking ≥ 20 g/day of 
alcohol, were excluded. Another 4 patients in whom 
liver stiffness could not be measured because of obesi-
ty or hepatic atrophy and 8 patients with large mea-
surement errors were also excluded from the evalua-
tion. In addition, another 16 patients, including 5 
patients who discontinued their hospital visits after 
DAA therapy and 9 patients without periodic SWE 
measurements, were withdrawn from the study. 
There were no patients with autoimmune hepatitis or 
cardiac failure. Therefore, data from 149 patients 
were finally used for the analysis（Figure 1）.
The DAAs used for treatment in 149 of these 
patients were sofosbuvir（SOF）, ledipasvir（LDV）in 
52 patients, ombitasvir/paritaprevir/ritonavir in 41 
patients, and SOF/ribavirin in 56 patients. Table 1 
shows the characteristics of the 149 patients（62 men, 
8 7 women；mean age 6 6 . 6±11 . 8 years）. Forty 
patients（26.9％）had previously received interferon
（IFN）therapy. Their mean ALT was 56.2±38.7（10-
252）IU/L, including a large number of hepatitis 
patients with relatively mild active disease. Other bio-
chemical values, AFP, M2BPGi, and Vs, were consis-
tent with chronic hepatitis or compensated liver cir-
rhosis. 
DAA therapy was continued for 12 weeks. All 149 
patients achieved SVR at follow-up 12.
Figure 2 shows the changes in Vs. Mean Vs 
decreased significantly during the 12-week treatment 
period, from 1.58±0.92 m/s at baseline to 1.46±0.27 
m/s at EOT（P＝0.00045）. Mean Vs at follow-up 12 
was 1.42±0.28 m/s, a significant decrease from the 
Vs at EOT（P＝0 . 0 0 002）. The mean difference 
between baseline and follow-up 12 of Vs（ΔVs）was 
0.147±0.164 m/s.
Figure 3 shows that Vs was significantly correlated 
with the FIB-4 index at baseline（r＝0.5483 , P＝
0 .0000）. Figure 4 shows the comparison of ΔVs 
between the group of patients with the FIB-4 index＜
3.25（n＝93）and the group of patients with the FIB-4 
index ≥ 3 .25（n＝56）. Although ΔVs tended to be 
????????　Flowchart of the study
A total of 206 consecutive hepatitis C patients were 
recruited. Twenty-nine of these patients, including six 
patients with a history of HCC, 20 patients diagnosed with 
fatty liver by ultrasound, and 9 patients with a history of 
drinking ≥  20 g/day of alcohol, were excluded. Another 12 
patients in whom liver stiffness could not be measured 
were also excluded from the evaluation. In addition, anoth-
er 16 patients who were lost to follow-up were withdrawn 
from the study. Data from 149 patients were finally used 
for the analysis. MLS；measure liver stiffness.
???????　Patient characteristics（n＝149）
Age（yr） 66.6±11.8
Sex（male/female） 62/87
Serotype（1/2） 92/57
IFN（Yes/No） 40/109
HCV RNA（LogIU/ml） 5.8±0.9
ALT（IU/L） 56.2±38.7
Total bilirubin（mg/dL） 0.83±0.29
Serum albmin（g/dL） 4.18±0.37
WBC（×103/mm3） 5.0±1.7
Hb（g/dL） 13.7±1.4
Platelet（×104/mm3） 16.1±5.5
Prothrombin time（％） 98.3±16.2
AFP（ng/mL） 9.7±19.7
Fib4 index 3.6±2.7
M2BPGi（C.O.I.） 3.0±3.3
Vs（m/s） 1.57±0.25
AFP：a-fetoprotein, ALT：alanine aminotransferase, 
Hb：hemoglobin, HCV：hepatitis C virus, IFN：interferon, 
M2BPGi：Mac-2 binding protein glycosylation isomer, 
Vs：velocity of shear wave, WBC：white blood cell.
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????????　Changes in Vs from baseline to follow-up 12
Mean Vs decreases significantly during the 12-week treatment 
period, from 1.58±0.92 m/s at baseline to 1.46±0.27 m/s at 
EOT（P＝0.00045）. Mean Vs at follow-up 12 is 1.42±0.28 m/s, 
a significant decrease from the Vs at EOT（P＝0.00002）.
????????　 Comparison of ΔVs between the group with the FIB-4 index
＜3.25 and the group with the FIB-4 index ≥ 3.25
Comparison of ΔVs between the group of patients with FIB-4 index ＜
3.25（n＝93）and the group of patients with FIB-4 index ≥ 3.25（n＝56）
shows that ΔVs tends to be greater in the group with a FIB-4 index 
≥ 3.25, but there is no significant difference（P＝0.05825）.
????????　 Relationship between Vs and the FIB-4 
index at baseline
Vs correlates significantly with the FIB-4 index at 
baseline（r＝0.5483, P＝0.0000）.
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greater in the group with a FIB-4 index ≥ 3.25, which 
indicates advanced fibrosis, no significant difference 
was observed（P＝0.05825）.
Table 2 shows the changes in each parameter from 
baseline to follow-up 12. The ALT, AFP, and M2BPGi 
levels decreased significantly at follow-up 12 from 
baseline. There were changes in the reference values, 
but total bilirubin, serum albumin, WBC and Plt levels 
increased significantly at follow-up 12 from baseline. 
Similarly, there was a change in the reference value, 
but prothrombin activity decreased significantly at fol-
low-up 12 from baseline.
From these results, we added ΔALT, ΔAFP, and Δ
M2BPGi as explanatory variables in the multiple 
regression analysis.
Table 3 shows the results of the multiple regression 
analysis for factors related to ΔVs. PT％ and ΔALT 
from baseline were significantly related to ΔVs. The 
ALT at baseline and the FIB4-index at baseline tend-
ed to affect ΔVs, but there were no significant rela-
???????　Changes of each parameters in baseline and follow-up 12
Baseline Follow-up 12 p value
ALT（IU/L） 56.2±38.7 17.8±10.2 0.0000
GGT（IU/L） 43.8±34.7 22.8±14.5 0.0000
Total bilirubin（mg/dL） 0.83±0.29 0.93±0.35 0.0000
Serum albmin（g/dL） 4.18±0.37 4.35±0.30 0.0000
WBC（×103/mm3） 5.0±1.7 5.3±1.6 0.0044
Hb（g/dL） 13.7±1.4 13.6±1.8 0.3065
Platelet（×104/mm3） 16.1±5.5 17.8±6.0 0.0000
Prothrombin time（％） 98.3±16.2 94.6±16.4 0.0004
AFP（ng/mL） 9.7±19.7 3.6±2.7 0.0000
M2BPGi（C.O.I.） 3.0±3.3 2.5±1.5 0.0000
Vs（m/s） 1.57±0.25 1.42±0.22 0.0000
AFP：a-fetoprotein, ALT：alanine aminotransferase, Hb：hemoglobin, 
HCV：hepatitis C virus, IFN：interferon, M2BPGi：Mac-2 binding protein 
glycosylation isomer, Vs：velocity of shear wave, WBC：white blood cell.
???????　Multiple regression analysis with ΔVs as the dependent variable
b SE std t P
Age（yr） −0.0008 0.0013 −0.0565 0.60548 0.54597
Sex −0.04 0.03094 −0.0119 1.29383 0.19813
ALT（IU/L） −0.0027 0.00148 −0.6327 1.82865 0.06985
Total bilirubin（mg/dL） 　0.0529 0.04799 　0.0937 1.10230 0.27247
Serum albmin（g/dL） −0.0569 0.04383 −0.1256 1.29858 0.19650
WBC（×103/mm3） 　0.01188 0.01044 　0.1230 1.18346 0.23889
Hb（g/dL） 　0.02098 0.01277 　0.1749 1.64263 0.10299
Platelet（×104/mm3） −0.0001 0.00382 −0.0034 0.02764 0.97800
Prothrombin time（％） 　0.00406 0.00092 　0.3970 4.39628 0.00002
AFP（ng/mL） −0.0039 0.00619 −0.4644 0.63013 0.52977
M2BPGi（C.O.I.） 　0.00249 0.0156 　0.0493 0.15963 0.87343
Fib4 Index 　0.01631 0.00927 　0.2669 1.75866 0.08108
ΔALT（IU/L） 　0.00346 0.00154 　0.7579 2.25017 0.02620
ΔAFP（ng/mL） 　0.00331 0.00643 　0.3662 0.51387 0.60826
ΔM2BPGi（C.O.I.） 　0.02149 0.0225 　0.2969 0.95513 0.34137
AFP：a-fetoprotein, ALT：alanine aminotransferase, Hb：hemoglobin, HCV：hepatitis C virus, 
IFN：interferon, M2BPGi：Mac-2 binding protein glycosylation isomer, Vs：velocity of shear 
wave, WBC：white blood cell.
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tions（P＝0.07056, P＝0.08108）.
??????????
Significant advances have been made in the treat-
ment of hepatitis C with the advent of DAAs. DAA 
therapy has milder side effects compared to IFN ther-
apy, and there is a high rate of SVR at 12 weeks 9〜13）. 
In the present study, SVR was achieved in all 149 
patients by 12-week DAA treatment.
It has been previously reported that Vs as mea-
sured by SWE is about 1.2 m/s in healthy livers 5）. In 
the present study, the mean Vs at baseline was 1.58
±0.92 m/s, but it decreased significantly to 1.46±
0.27 m/s during a short 12-week period of DAA ther-
apy. Vs at follow-up 12 further decreased significantly 
to 1.42±0.28 m/s. Liver stiffness shown as Vs is influ-
enced not only by the degree of liver stiffness, but 
also by necroinflammatory activity 14,15）. Elevated ALT 
levels in the present study, corresponding to the pres-
ence of necroinflammatory activity, decreased signifi-
cantly from baseline to EOT. Therefore, the reduction 
of ALT levels from baseline to EOT appeared strong-
ly associated with the reduction of liver stiffness as 
shown by SWE.
Marcellin et al. who performed multiple liver biop-
sies in patients with SVR after IFN therapy, reported 
histologic improvement in inflammation after treat-
ment was completed, but they found no clear evi-
dence of fibrosis improvement even after follow-up 
for 3 years or longer 16）. Therefore, improvement of 
hepatic fibrosis in the present patients after a short 
12-week treatment period was not to be expected. 
The improvement in Vs should be considered to 
reflect remission of inflammation, rather than improve-
ment in fibrosis.
Previous studies showed that the FIB-4 index can 
be used to classify liver disease and monitor HCV-
infected patients in longitudinal studies 17,18）.
Ogasawara et al. showed a positive correlation 
between baseline liver stiffness and the FIB-4 index, 
and more prominent improvement of liver stiffness by 
DAAs in patients with hepatic cirrhosis with a FIB-4 
index ≥ 3.25 than in patients with chronic hepatitis 
with a FIB-4 index ＜3.25 7）. In the present study, the 
positive correlation between baseline liver stiffness 
and the FIB-4 index was confirmed. Although ΔVs 
tended to be greater in the group of patients with a 
baseline FIB-4 index ≥ 3 .25 than in the group of 
patients with a baseline FIB-4 index ＜3.25, no signifi-
cant difference was observed（P＝0.05825）.
M2BPGi is a new liver fibrosis marker that quanti-
tatively measures changes in the carbohydrate struc-
ture of Mac-2 binding protein 19）, and it is also consid-
ered useful in predicting carcinogenesis in hepatitis C 
patients 20〜22）. In the present study, M2BPGi, which at 
baseline was 2.93±2.62 C.O.I., or about 3-times the 
upper normal limit, decreased significantly at EOT to 
1.58±1.30 C.O.I. Therefore, it is assumed that elevat-
ed M2BPGi, like Vs, is not only due to hepatic fibrosis, 
but also due to effects caused by inflammation 23）.
As factors contributing to the improvement of Vs, 
PT％ and ΔALT were identified as significant in the 
present study. Pre-treatment ALT and the FIB-4 
index were confirmed to greatly affect the improve-
ment of Vs. Thus, the present study showed that 
DAAs improve l iver sti f fness in patients with 
advanced fibrosis whose liver was severely inflamed 
before treatment and whose protein-synthesizing 
capability is sufficiently maintained.
???????????
This study was conducted at a single institution, 
and although this was a prospective study in which 
206 patients were enrolled, data from a smaller num-
ber, only 149 patients, could be used for evaluation. 
Since no patients underwent liver biopsy in this 
study, the histopathological findings and Vs could not 
be compared.
???????????
Vs measured by SWE in hepatitis C patients 
improved with 12 weeks of DAA therapy. This 
improvement continued until follow-up 12（12 weeks 
after EOT）. The significant factors that contribute to 
the improvement of Vs during DAA treatment are 
baseline PT％ and ΔALT. The FIB-4 index also has a 
great effect on the improvement.
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